{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:09Z","timestamp":1792788009169,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2019YFA0904404"],"award-info":[{"award-number":["2019YFA0904404"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272848"],"award-info":[{"award-number":["82272848"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key R&D Program of China, Stem Cell Research and Organ Repair","award":["2022YFA1106500"],"award-info":[{"award-number":["2022YFA1106500"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06365-x","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T06:36:26Z","timestamp":1745476586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Fenghao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhen","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-an","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaozhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2266-7872","authenticated-orcid":false,"given":"Yan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"6365_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.semcancer.2019.09.013","volume":"61","author":"KW Nassar","year":"2020","unstructured":"Nassar KW, Tan AC. The mutational landscape of mucosal melanoma. Semin Cancer Biol. 2020;61:139\u201348.","journal-title":"Semin Cancer Biol"},{"issue":"16","key":"6365_CR2","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1158\/1078-0432.CCR-13-0739","volume":"19","author":"B Lian","year":"2013","unstructured":"Lian B, Si L, Cui C, Chi Z, Sheng X, Mao L, et al. Phase II randomized trial comparing high-dose IFN-\u03b12b with Temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res. 2013;19(16):4488\u201398.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"6365_CR3","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/cncr.20866","volume":"103","author":"CC McLaughlin","year":"2005","unstructured":"McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103(5):1000\u20137.","journal-title":"Cancer"},{"issue":"2","key":"6365_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin"},{"issue":"7653","key":"6365_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175\u201380.","journal-title":"Nature"},{"issue":"1","key":"6365_CR6","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","volume":"10","author":"F Newell","year":"2019","unstructured":"Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun. 2019;10(1):3163.","journal-title":"Nat Commun"},{"issue":"8","key":"6365_CR7","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","volume":"83","author":"AE Chang","year":"1998","unstructured":"Chang AE, Karnell LH, Menck HR. The National cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American college of surgeons commission on cancer and the American cancer society. Cancer. 1998;83(8):1664\u201378.","journal-title":"Cancer"},{"issue":"6","key":"6365_CR8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","volume":"12","author":"L Si","year":"2019","unstructured":"Si L, Zhang X, Shu Y, Pan H, Wu D, Liu J, et al. A phase Ib study of pembrolizumab as Second-Line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151). Transl Oncol. 2019;12(6):828\u201335.","journal-title":"Transl Oncol"},{"issue":"16","key":"6365_CR9","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1158\/1078-0432.CCR-19-3922","volume":"26","author":"B Tang","year":"2020","unstructured":"Tang B, Chi Z, Chen Y, Liu X, Wu D, Chen J, et al. Safety, efficacy, and biomarker analysis of Toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial. Clin Cancer Res. 2020;26(16):4250\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6365_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bjd.21241","volume":"187","author":"X Bai","year":"2022","unstructured":"Bai X, Shoushtari AN, Betof Warner A, Si L, Tang B, Cui C, et al. Benefit and toxicity of programmed death-1 Blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. Br J Dermatol. 2022;187(3):401\u201310.","journal-title":"Br J Dermatol"},{"issue":"3","key":"6365_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399.","journal-title":"Nat Rev Drug Discov"},{"issue":"23","key":"6365_CR12","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, van den Borch TH, Met \u00d6, Kessels R, Geukes Foppen MH, et al. Tumor-Infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med. 2022;387(23):2113\u201325.","journal-title":"N Engl J Med"},{"issue":"8","key":"6365_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"6","key":"6365_CR14","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023;41(6):1265\u201374.","journal-title":"J Clin Oncol"},{"issue":"15","key":"6365_CR15","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","volume":"26","author":"D Shi","year":"2020","unstructured":"Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, et al. Chimeric antigen Receptor-Glypican-3 T-Cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res. 2020;26(15):3979\u201389.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"6365_CR16","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in Gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189\u201398.","journal-title":"Nat Med"},{"issue":"2","key":"6365_CR17","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1158\/1078-0432.CCR-16-1203","volume":"23","author":"H Liu","year":"2017","unstructured":"Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, et al. Targeting Alpha-Fetoprotein (AFP)-MHC complex with CAR T-Cell therapy for liver cancer. Clin Cancer Res. 2017;23(2):478\u201388.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"6365_CR18","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1172\/JCI43490","volume":"120","author":"D Chinnasamy","year":"2010","unstructured":"Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest. 2010;120(11):3953\u201368.","journal-title":"J Clin Invest"},{"key":"6365_CR19","doi-asserted-by":"publisher","first-page":"16024","DOI":"10.1038\/mto.2016.24","volume":"3","author":"K Inoo","year":"2016","unstructured":"Inoo K, Inagaki R, Fujiwara K, Sasawatari S, Kamigaki T, Nakagawa S, et al. Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research. Mol Ther Oncolytics. 2016;3:16024.","journal-title":"Mol Ther Oncolytics"},{"issue":"11","key":"6365_CR20","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/0008-5472.CAN-12-3913","volume":"73","author":"D Chinnasamy","year":"2013","unstructured":"Chinnasamy D, Tran E, Yu Z, Morgan RA, Restifo NP, Rosenberg SA. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Res. 2013;73(11):3371\u201380.","journal-title":"Cancer Res"},{"issue":"6","key":"6365_CR21","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/mt.2016.63","volume":"24","author":"T Gargett","year":"2016","unstructured":"Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 Blockade. Mol Ther. 2016;24(6):1135\u201349.","journal-title":"Mol Ther"},{"issue":"18","key":"6365_CR22","doi-asserted-by":"publisher","first-page":"5852","DOI":"10.1158\/1078-0432.CCR-08-3163","volume":"15","author":"E Yvon","year":"2009","unstructured":"Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Dutour A, Anichini A, et al. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009;15(18):5852\u201360.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"6365_CR23","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.7150\/thno.43991","volume":"10","author":"M Yang","year":"2020","unstructured":"Yang M, Tang X, Zhang Z, Gu L, Wei H, Zhao S, et al. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics. 2020;10(17):7622\u201334.","journal-title":"Theranostics"},{"key":"6365_CR24","doi-asserted-by":"crossref","unstructured":"Simon B, Harrer DC, Schuler-Thurner B, Schuler G, Uslu U. Arming T cells with a gp100-Specific TCR and a CSPG4-Specific CAR using combined DNA- and RNA-Based receptor transfer. Cancers (Basel). 2019;11(5).","DOI":"10.3390\/cancers11050696"},{"issue":"7","key":"6365_CR25","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917\u201324.","journal-title":"J Clin Oncol"},{"issue":"6","key":"6365_CR26","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1073\/pnas.1009069108","volume":"108","author":"P Schmidt","year":"2011","unstructured":"Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H. Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci U S A. 2011;108(6):2474\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6365_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","volume":"17","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Jiang C, Liu Z, Yang M, Tang X, Wang Y, et al. B7-H3-Targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors. Mol Ther Oncolytics. 2020;17:180\u20139.","journal-title":"Mol Ther Oncolytics"},{"key":"6365_CR28","doi-asserted-by":"crossref","unstructured":"Soltantoyeh T, Akbari B, Karimi A, Mahmoodi Chalbatani G, Ghahri-Saremi N, Hadjati J et al. Chimeric antigen receptor (CAR) T cell therapy for metastatic melanoma: challenges and road ahead. Cells. 2021;10(6).","DOI":"10.3390\/cells10061450"},{"issue":"3","key":"6365_CR29","first-page":"841","volume":"47","author":"JM Lehmann","year":"1987","unstructured":"Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethm\u00fcller G, Johnson JP. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res. 1987;47(3):841\u20135.","journal-title":"Cancer Res"},{"issue":"24","key":"6365_CR30","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1073\/pnas.86.24.9891","volume":"86","author":"JM Lehmann","year":"1989","unstructured":"Lehmann JM, Riethm\u00fcller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the Immunoglobulin superfamily. Proc Natl Acad Sci U S A. 1989;86(24):9891\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6365_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P","volume":"189","author":"IM Shih","year":"1999","unstructured":"Shih IM. The role of CD146 (Mel-CAM) in biology and pathology. J Pathol. 1999;189(1):4\u201311.","journal-title":"J Pathol"},{"issue":"3","key":"6365_CR32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3727\/096504017X15031557924123","volume":"26","author":"IW Sumardika","year":"2018","unstructured":"Sumardika IW, Youyi C, Kondo E, Inoue Y, Ruma IMW, Murata H, et al. \u03b2-1,3-Galactosyl-O-Glycosyl-Glycoprotein \u03b2-1,6-N-Acetylglucosaminyltransferase 3 increases MCAM stability, which enhances S100A8\/A9-Mediated cancer motility. Oncol Res. 2018;26(3):431\u201344.","journal-title":"Oncol Res"},{"issue":"Pt 1","key":"6365_CR33","first-page":"95","volume":"213","author":"JP Johnson","year":"1996","unstructured":"Johnson JP, Rummel MM, Rothb\u00e4cher U, Sers C. MUC18: A cell adhesion molecule with a potential role in tumor growth and tumor cell dissemination. Curr Top Microbiol Immunol. 1996;213(Pt 1):95\u2013105.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"6365_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12010-016-2218-1","volume":"181","author":"M Mohammadi","year":"2017","unstructured":"Mohammadi M, Nejatollahi F, Ghasemi Y, Faraji SN. Anti-Metastatic and Anti-Invasion effects of a specific Anti-MUC18 ScFv antibody on breast cancer cells. Appl Biochem Biotechnol. 2017;181(1):379\u201390.","journal-title":"Appl Biochem Biotechnol"},{"issue":"1","key":"6365_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13046-020-01722-8","volume":"39","author":"R Feng","year":"2020","unstructured":"Feng R, Wang Y, Ramachandran V, Ma Q, May MM, Li M, et al. Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma. J Exp Clin Cancer Res. 2020;39(1):273.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"6365_CR36","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s13402-022-00682-9","volume":"45","author":"R Zhang","year":"2022","unstructured":"Zhang R, Chen X, Chen S, Tang J, Chen F, Lin Y, et al. Inhibition of CD146 lessens uveal melanoma progression through reducing angiogenesis and vasculogenic mimicry. Cell Oncol (Dordr). 2022;45(4):557\u201372.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"6365_CR37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1182\/blood-2002-04-1004","volume":"102","author":"X Yan","year":"2003","unstructured":"Yan X, Lin Y, Yang D, Shen Y, Yuan M, Zhang Z, et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood. 2003;102(1):184\u201391.","journal-title":"Blood"},{"issue":"42","key":"6365_CR38","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1038\/onc.2016.83","volume":"35","author":"J Stalin","year":"2016","unstructured":"Stalin J, Nollet M, Garigue P, Fernandez S, Vivancos L, Essaadi A, et al. Targeting soluble CD146 with a neutralizing antibody inhibits vascularization, growth and survival of CD146-positive tumors. Oncogene. 2016;35(42):5489\u2013500.","journal-title":"Oncogene"},{"issue":"22","key":"6365_CR39","doi-asserted-by":"publisher","first-page":"9609","DOI":"10.1021\/acs.nanolett.1c03377","volume":"21","author":"J Liu","year":"2021","unstructured":"Liu J, Kang L, Smith S, Wang C. Transmembrane MUC18 targeted polydopamine nanoparticles and a mild photothermal effect synergistically disrupt actin cytoskeleton and migration of cancer cells. Nano Lett. 2021;21(22):9609\u201318.","journal-title":"Nano Lett"},{"key":"6365_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jcis.2024.07.047","volume":"676","author":"X Yu","year":"2024","unstructured":"Yu X, Liu J, Bauer A, Wei X, Smith S, Ning S, et al. Enhancing tumor endothelial permeability using MUC18-targeted gold nanorods and mild hyperthermia. J Colloid Interface Sci. 2024;676:101\u20139.","journal-title":"J Colloid Interface Sci"},{"issue":"22","key":"6365_CR41","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1158\/0008-5472.CAN-23-1356","volume":"83","author":"J Shi","year":"2023","unstructured":"Shi J, Jiao T, Guo Q, Weng W, Ma L, Zhang Q, et al. A cell Surface-Binding antibody atlas nominates a MUC18-Directed antibody-Drug conjugate for targeting melanoma. Cancer Res. 2023;83(22):3783\u201395.","journal-title":"Cancer Res"},{"issue":"22","key":"6365_CR42","doi-asserted-by":"publisher","first-page":"E4990","DOI":"10.1073\/pnas.1716788115","volume":"115","author":"DF Tucker","year":"2018","unstructured":"Tucker DF, Sullivan JT, Mattia KA, Fisher CR, Barnes T, Mabila MN, et al. Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles. Proc Natl Acad Sci U S A. 2018;115(22):E4990\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6365_CR43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12964-020-00617-7","volume":"18","author":"D Liu","year":"2020","unstructured":"Liu D, Badeti S, Dotti G, Jiang JG, Wang H, Dermody J, et al. The role of immunological synapse in predicting the efficacy of chimeric antigen receptor (CAR) immunotherapy. Cell Commun Signal. 2020;18(1):134.","journal-title":"Cell Commun Signal"},{"issue":"25","key":"6365_CR44","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","volume":"184","author":"CR Good","year":"2021","unstructured":"Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell. 2021;184(25):6081\u2013e10026.","journal-title":"Cell"},{"key":"6365_CR45","unstructured":"Ding YLX, He T, Liang M, Qi F. Beijing Imunopharm Technology Co., Ltd, CN116836282B."},{"issue":"4","key":"6365_CR46","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1158\/2159-8290.CD-22-0787","volume":"13","author":"P Dharanipragada","year":"2023","unstructured":"Dharanipragada P, Zhang X, Liu S, Lomeli SH, Hong A, Wang Y, et al. Blocking genomic instability prevents acquired resistance to MAPK inhibitor therapy in melanoma. Cancer Discov. 2023;13(4):880\u2013909.","journal-title":"Cancer Discov"},{"key":"6365_CR47","doi-asserted-by":"crossref","unstructured":"Yu Z, Shi J, Fang Y, Zhao Y, Xu A, Li N. Developing innovative strategies of tumor\u2013infiltrating lymphocyte therapy for tumor treatment. Oncol Rep. 2024;51(6).","DOI":"10.3892\/or.2024.8744"},{"key":"6365_CR48","doi-asserted-by":"crossref","unstructured":"Gargett T, Truong NTH, Gardam B, Yu W, Ebert LM, Johnson A et al. Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers. J Immunother Cancer. 2024;12(5).","DOI":"10.1136\/jitc-2023-008659"},{"issue":"1","key":"6365_CR49","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41467-024-45221-2","volume":"15","author":"S Jilani","year":"2024","unstructured":"Jilani S, Saco JD, Mugarza E, Pujol-Morcillo A, Chokry J, Ng C, et al. CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes. Nat Commun. 2024;15(1):1244.","journal-title":"Nat Commun"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06365-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06365-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06365-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T07:03:59Z","timestamp":1745478239000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06365-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6365"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06365-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"16 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal care and experimental procedures were carried out in accordance with Animal Care Ethics and were approved by the Medical Ethics Committee of the Beijing Cancer Hospital & Institute.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"473"}}